Oak Grove Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Oak Grove Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,000	Closed	-$397K	–	62
2022 Q3	$397K	Buy	+5,000	New	+$422K	0.13%	47
2019 Q3	–	Sell	-29,380	Closed	-$2.58M	–	81
2019 Q2	$2.58M	Buy	29,380 +3,575	+14%	+$305K	1.38%	21
2019 Q1	$2.34M	Buy	25,805 +11,655	+82%	+$992K	1.47%	18
2018 Q4	$1.01M	Buy	14,150 +1,600	+13%	+$129K	0.91%	24
2018 Q3	$1.2M	Buy	12,550 +2,950	+31%	+$286K	1.04%	25
2018 Q2	$914K	Buy	9,600 +3,150	+49%	+$290K	0.93%	23
2018 Q1	$566K	Buy	+6,450	New	+$589K	0.62%	32

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Oak Grove Capital's XBI Position: Q4 2022 in Review

Oak Grove Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 5,000 shares — an estimated $397K sold.

Oak Grove Capital first reported a position in XBI in Q1 2018 and held it in 7 quarters. The position peaked at $2.58M in Q2 2019. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Oak Grove Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
Oak Grove Capital sold 5,000 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $397K.
Oak Grove Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and held it in 7 quarters.
Oak Grove Capital's State Street SPDR S&P Biotech ETF position peaked at $2.58M in Q2 2019.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Oak Grove Capital's 13F filing for Q4 2022, filed 8 Feb 2023.